SEHK:2157Biotechs
Assessing Lepu Biopharma’s Valuation After Earnings Turnaround And Share Price Surge
Earnings turnaround puts Lepu Biopharma back on investors’ radar
Lepu Biopharma (SEHK:2157) has drawn fresh attention after reporting full year 2025 results that shifted from a net loss to net income of CNY 261.36 million, with sales of CNY 934.87 million.
The company also moved from a basic loss per share of CNY 0.24 to basic earnings per share of CNY 0.15 from continuing operations, a change that gives investors new financial data points to assess the stock.
See our latest analysis for Lepu...